Eledon Pharmaceuticals Inc
ELDN3.365USD
-0.015-0.44%
交易中 （美东）报价延迟15分钟
201.50M总市值
7.21市盈率 TTM
关于 Eledon Pharmaceuticals Inc 公司
Eledon Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司正在开发用于管理和治疗危及生命的疾病的免疫调节疗法。该公司的主要研究产品是 tegoprubart，这是一种对 CD40 配体具有高亲和力的抗 CD40L 抗体，CD40 配体是共刺激 CD40/CD40L 细胞通路中经过充分验证的生物靶点。CD40L 信号在适应性和先天性免疫细胞活化和功能中的核心作用使其成为非淋巴细胞耗竭、免疫调节治疗干预的有吸引力的靶点。Tegoprubart 的设计旨在潜在地提高安全性并提供药代动力学、药效学和剂量优势。CD40L 主要在活化的 CD4+ T 细胞、血小板和内皮细胞上表达，而 CD40 受体则在抗原呈递细胞（如巨噬细胞和树突状细胞）以及 B 细胞上组成性表达。
公司简介
公司代码ELDN
公司名称Eledon Pharmaceuticals Inc
上市日期Sep 17, 2014
CEODr. David-Alexandre C. (DA) Gros, M.D.
员工数量31
证券类型Ordinary Share
年结日Sep 17
公司地址19800 Macarthur Blvd.
城市IRVINE
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编92612
电话19492388090
网址https://eledon.com/
公司代码ELDN
上市日期Sep 17, 2014
CEODr. David-Alexandre C. (DA) Gros, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. David-Alexandre C. (DA) Gros, M.D.
Dr. David-Alexandre C. (DA) Gros, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
9.00K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
677.00
--
Dr. Allan D. Kirk, M.D., Ph.D.
Dr. Allan D. Kirk, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Bryan E. Smith, J.D.
Mr. Bryan E. Smith, J.D.
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. James Robinson
Mr. James Robinson
Independent Director
Independent Director
--
--
Dr. Jan Hillson, M.D.
Dr. Jan Hillson, M.D.
Independent Director
Independent Director
--
--
Dr. June Lee, M.D.
Dr. June Lee, M.D.
Independent Director
Independent Director
--
--
Dr. Steven N. Perrin, Ph.D.
Dr. Steven N. Perrin, Ph.D.
President, Chief Scientific Officer, Director
President, Chief Scientific Officer, Director
--
--
Mr. John S. McBride
Mr. John S. McBride
Independent Director
Independent Director
--
--
Mr. Paul Little
Mr. Paul Little
Chief Financial Officer
Chief Financial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. David-Alexandre C. (DA) Gros, M.D.
Dr. David-Alexandre C. (DA) Gros, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
9.00K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
677.00
--
Dr. Allan D. Kirk, M.D., Ph.D.
Dr. Allan D. Kirk, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Bryan E. Smith, J.D.
Mr. Bryan E. Smith, J.D.
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. James Robinson
Mr. James Robinson
Independent Director
Independent Director
--
--
Dr. Jan Hillson, M.D.
Dr. Jan Hillson, M.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月4日 周五
更新时间: 7月4日 周五
持股股东
股东类型
持股股东
持股股东
占比
BVF Partners L.P.
10.51%
RA Capital Management, LP
5.96%
The Vanguard Group, Inc.
5.54%
First Light Asset Management, LLC
3.89%
Sphera Funds Management Ltd.
3.85%
Other
70.25%
持股股东
持股股东
占比
BVF Partners L.P.
10.51%
RA Capital Management, LP
5.96%
The Vanguard Group, Inc.
5.54%
First Light Asset Management, LLC
3.89%
Sphera Funds Management Ltd.
3.85%
Other
70.25%
股东类型
持股股东
占比
Hedge Fund
28.61%
Investment Advisor
17.21%
Investment Advisor/Hedge Fund
10.61%
Venture Capital
5.96%
Corporation
1.36%
Research Firm
1.17%
Pension Fund
0.12%
Family Office
0.07%
Individual Investor
0.03%
Other
34.87%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
126
38.97M
65.08%
-2.26M
2025Q1
124
39.32M
65.66%
-3.87M
2024Q4
105
38.47M
64.39%
+11.26M
2024Q3
70
19.89M
51.00%
-1.66M
2024Q2
71
20.04M
55.99%
+4.61M
2024Q1
65
11.37M
47.26%
-1.53M
2023Q4
63
10.93M
50.76%
-2.06M
2023Q3
65
10.70M
50.83%
-4.12M
2023Q2
66
11.20M
53.85%
+179.31K
2023Q1
67
8.42M
61.13%
-3.83M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BVF Partners L.P.
6.29M
10.51%
--
--
Mar 31, 2025
RA Capital Management, LP
3.57M
5.96%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.95M
4.93%
+58.49K
+2.02%
Mar 31, 2025
First Light Asset Management, LLC
2.33M
3.89%
--
--
Mar 31, 2025
Sphera Funds Management Ltd.
2.31M
3.85%
-244.50K
-9.58%
Mar 31, 2025
Blue Owl Capital Holdings LP
1.82M
3.04%
-140.00K
-7.14%
Mar 31, 2025
Woodline Partners LP
1.67M
2.79%
--
--
Mar 31, 2025
Susquehanna International Group, LLP
1.59M
2.65%
+1.32M
+489.41%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
1.32M
2.2%
-196.91K
-12.99%
Mar 31, 2025
Ensign Peak Advisors, Inc.
1.26M
2.11%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.04%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Inspire Fidelis Multi Factor ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.04%
Global X Russell 2000 ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0.01%
ALPS Medical Breakthroughs ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
Inspire Fidelis Multi Factor ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
公告日期
类型
比率
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
